BNP Paribas Financial Markets
SGMT icon

BNP Paribas Financial Markets’s Sagimet Biosciences SGMT Stock Holding History

BNP Paribas Financial Markets’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$928K Buy
120,036
+96,970
+420% +$659K ﹤0.01% 3364
2026
Q1 		$121K Sell
23,066
-52,060
-69% -$290K ﹤0.01% 4281
2025
Q4 		$445K Buy
75,126
+74,769
+20,944% +$537K ﹤0.01% 3633
2025
Q3 		$2.45K Sell
357
-26,428
-99% -$214K ﹤0.01% 5153
2025
Q2 		$204K Buy
26,785
+26,496
+9,168% +$112K ﹤0.01% 3764
2025
Q1 		$942 Sell
289
-1,688
-85% -$7.08K ﹤0.01% 5081
2024
Q4 		$8.9K Buy
+1,977
New +$10K ﹤0.01% 4861

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BNP Paribas Financial Markets's SGMT Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Sagimet Biosciences (SGMT) stake by 420% in Q2 2026, buying an estimated $659K and bringing the position to 120,036 shares worth $928K. The position accounts for ﹤0.01% of the portfolio, ranked #3364.

BNP Paribas Financial Markets first reported a position in SGMT in Q4 2024 and has held it in 7 quarters since. 110 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • BNP Paribas Financial Markets held 120,036 shares of Sagimet Biosciences worth $928K as of Q2 2026.
  • BNP Paribas Financial Markets bought 96,970 Sagimet Biosciences shares in Q2 2026, an estimated $659K.
  • Sagimet Biosciences made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3364 holding.
  • BNP Paribas Financial Markets first reported a position in Sagimet Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 110 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.